Q4 2025 Rxsight Inc Earnings Call Transcript
Key Points
- RxSight Inc (RXST) reported a 17% increase in LDD install base, reaching 1,134 units by the end of 2025.
- LAL revenue accounted for an all-time high of 86% of total company sales in Q4 2025, contributing to a gross margin of 77.5%.
- The company ended 2025 with no debt and approximately $228 million in cash equivalents and short-term investments.
- RxSight Inc (RXST) is focusing on international expansion, with approvals in the EU, UK, South Korea, Singapore, and Australia.
- The company is committed to innovation, with over 20 FDA approvals in the past five years, and plans for further product development.
- Q4 2025 sales were down 19% year over year due to lower LDD sales.
- The company reported a net loss of $9.2 million in Q4 2025, with an adjusted net loss of $1.3 million.
- 2026 revenue guidance implies a year-over-year decline of approximately 5% at the midpoint, primarily due to lower LDD sales.
- Gross margin guidance for 2026 is lower than 2025 levels, reflecting higher cost inventory and manufacturing absorption headwinds.
- Operating expenses are expected to increase in 2026, driven by ongoing investments in international expansion and US sales and marketing efforts.
Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the RX site 4th quarter 2025 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star, followed with the number 1 on your telephone keypad. If you would like to withdraw your question, press one again.
Thank you. I would now like to turn the call over to Oliver Murazevic, Vice President of investor relations. Please go ahead.
Thank you, operator. Presenting today are RXI President and Chief Executive Officer Dr. Ron Kurtz and Chief Financial Officer Mark Walterd. Earlier today, RXI released financial results for the three months ended December 30th, 2025. A copy of the press release is available on the company's website.
Before we begin, I would like to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
